Maternal and infant outcome after pamidronate treatment of polyostotic fibrous dysplasia and osteogenesis imperfecta before conception: A report of four cases

Journal of Clinical Endocrinology and Metabolism

Volumn 91, Issue 6, 2006, Pages 2017-2020

  Chan, Brendan ^a   Zacharin, Margaret ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

PAMIDRONIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; ALBRIGHT SYNDROME; ANAMNESIS; BONE DENSITY; BONE RADIOGRAPHY; CASE REPORT; CLINICAL FEATURE; CONCEPTION; CONFERENCE PAPER; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; LONG BONE; OSTEOGENESIS IMPERFECTA; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROGENY; SKELETON MALFORMATION; VAGINAL DELIVERY;

ADULT; BONE AND BONES; CALCIUM; DIPHOSPHONATES; FEMALE; FETUS; FIBROUS DYSPLASIA, POLYOSTOTIC; HUMANS; OSTEOGENESIS IMPERFECTA;

EID: 33744953434     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2005-2548     Document Type: Conference Paper

References (13)

1. Liens B, Delmas PD, Meunier PJ 1994 Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 343:953-954
2. Chapurlat RB, Delmas PD, Liens D, Meunier PJ 1997 Long-term effect of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 12:1746-1752
3. Glorieux FH, Bishop N, Plotkin H, Chabot G, Lanque R, Travers R 1998 Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 339:947-952
4. Astrom E, Soderhall S 2002 Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta. Arch Dis Child 86:356-364
5. Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, Beneton MN, Gertz BJ, Sciberras DG, Holland SD, Orgee J, Coombes GM, Rogers SR, Porras AG 1997 Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 12:1700-1707
6. Munns C, Rauch F, Ward L, Glorieux F 2004 Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases. J Bone Miner Res 19:1742-1745
7. Graepel P, Bentley P, Fritz H, Miyamoto M, Slater SR 1992 Reproduction toxicity studies with pamidronate. Arneimittelforschung 42:654-667
8. Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A 1999 Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology 60:68-73
9. Cremers SC, Papapoulos SE, Gelderblom H, Seynaeve C, Den Hartigh J, Vermeijj P, van de Rijt CC, Zuylen L 2005 Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases. J Bone Miner Res 20:1543-1547
10. Illidge T, Hussey M, Godden C 1996 Malignant hypercalcaemia in pregnancy and antenatal administration of intravenous pamidronate Clin Oncol 8:257-258
11. Yarrington JT, Capen CC, Black HE, Re R, Potts Jr JT, Geho WB 1976 Experimental parturient hypocalcemia in cows following prepartal chemical inhibition of bone resorption. Am J Pathol 83:569-587
12. Siminoskis K, Fitzgerald A, Flesch G, Gross M 2000 Intravenous pamidronate for treatment of reflex sympathetic dystrophy during breast feeding. J Bone Miner Res 15:2052-2055
13. Kelly T 1990 Bone mineral density reference databases for American men and women. J Bone Miner Res 5(Suppl 2):S249